NervGen Pharma’s Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper

NervGen Pharma’s Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper Vancouver, British Columbia–(Newsfile Corp. – July 10, 2019) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative...